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The role of prostanoids in a swine model of co/0nary 
artery spasm was examined. Eighteen miniature pigs 
underwent endothelial denudation of the left coronary 
artery (left circumflex branch in 14 pigs and left anterior 
descending branch in 4 pigs) followed by high cholesterol 
feeding. Three months after the denudation, when coro-
nary artery spasm was repeatedly provoked along the 
denuded portion of the coronary artery by histamine, 
the vasoconstrictive effect of thromboxane A2 and the 
preventive effects of indomethacin and prostacyclin against 
histamine-induced coronary artery spasm were eXllm-
ined. Intracoronary administration of thiothromboxane 
A2, 200 f,Lg, a stable thromboxane A2 analog, failed to 
Considerable attention has been directed to the potential role 
of prostanoids in the modulation of coronary vascular tone 
(1-3), especially thromboxane A2, a potent vasoconstrictor 
released from blood platelets (4), and prostacyclin, a potent 
vasodilator synthesized in the vessel wall (5), particularly 
in the endothelium (6). Abnormally activated platelet func-
tion, such as platelet aggregation and release of thrombox-
ane A2, has been noted in patients with ischemic heart dis-
ease (7-11) during and immediately after vasospastic angina 
(12-15). Moncada and Vane (16) and Hirsh et al. (17) 
suggested that a thromboxane A2/prostacyclin imbalance 
may be one explanation for many of the pathophysiologic 
manifestations of vascular disease, including ischemic heart 
disease. However, it is not clear whether this imbalance 
(9,16) or an increase in thromboxane A2 level (14,18) is 
the cause or the result of vasospastic angina (12-15). 
Recently, we succeeded in provoking coronary artery 
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provoke coronary artery spasm (seven of seven cases) 
but nonselectively constricted the coronary artery by 
33 %. Intravenous administration of indomethacin, 2 
mg/kg, or continuous intravenous hlfusion of prostacy-
c1in, 50 ng/kg per min, failed to prevent histamine-in-
duced coronary artery spasm (four of four and eight of 
eight cases, respectively), yet the spasm was all but pre-
vented by intravenous pretreatment with diphenhydra-
mine at a dose of 1 mg/kg. Thus, in this swine model, 
prostanoids may not play a priQlary role in the occur-
rence of coronary artery spasm. 
(J Am Coil CardioI1985;6:321-7) 
spasm in atherosclerotic miniature swine (19), In this model, 
coronary artery spasm was provoked repeatedly by hista-
mine along the experimentally induced atherosclerotic por-
tion of the coronary artery, Accordingly, in the present study 
using this swine model, we examined the role ofprostanoids 
in the provocation and prevention of angiographically de-
termined coronary artery spasm, 
Methods 
Animal preparation. Eighteen male G6ttingen minia-
ture swine, 4 to 5 months of age (mean 4.9 ± 0.2) and 
weighing 13.5 to 17.0 kg (mean 15.0 ± 0,5), were anes-
thetized with an intramuscular administration of ketamine 
hydrochloride, 12.5 mg/kg body weight, followed by in-
travenous administration of sodium pentobarbital, 12.5 mglkg. 
After intravenous pretreatment with lidocaine, 2 mg/kg, the 
swine underwent endothelial denudation using a 2F Fogarty 
catheter inserted approximately 3 em into the proximal por-
tion of the left coronary artery: the left circumflex branch 
in 14 pigs and the left anterior descending branch in 4 pigs, 
as previously described (20). Aortic pressure was monitored 
with a Statham P23Db pressure transducer simultaneously 
with the electrocardiogram in the limb leads and two pre-
cordial leads (3V2 and V6 ). After the denudation, the swine 
were fed a laboratory chow diet containing 2% cholesterol, 
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and the daily food intake was limited to 3% of body weight 
to prevent excessive weight gain. 
Coronary arteriography and hemodynamic record-
ing. The responses of the coronary arteries to various va-
soconstrictive or vasodilatory stimuli were evaluated quan-
titatively by selective coronary arteriography. Coronary 
cineangiograms in a left anterior oblique projection were 
obtained by manually injecting 5 ml of contrast medium 
(Urographin 76, Nihon Schering) through a preshaped green 
Kifa catheter and filmed at 48 frames/s on 35 mm cinefilm 
(CFS 746, Kodak) loaded on an Arriflex cine-camera at 400 
rnA and 84 to 100 k V, depending on the thoracic size. Aortic 
pressure and electrocardiogram in leads I, II, III, aVL, 3V2 
and V 6 were simultaneously recorded on a multichannel 
oscillograph (San-Ei Polygraph System) and the data were 
stored on tape using an FM data recorder (R-21O, TEAC) 
for subsequent data analysis. Arterial pH, partial pressure 
of oxygen (Po2) and carbon monoxide (PC02) and base 
excess were maintained within a normal range. 
Protocols. Before endothelial denudation, coronary ar-
teriography was performed in the control state, after intra-
venous administration of nitroglycerin, 20 j.Lg/kg, and after 
intracoronary administration of histamine, 200 j.Lg, with 
pretreatment with cimetidine, 60 mg/kg intravenously. Ci-
metidine was given to block the Hrreceptor. In our pre-
liminary study using six miniature swine 3 months after 
de-endothelialization, intracoronary administration of his-
tamine, 200 j.Lg, enhanced the vasoconstriction along the de-
nuded portion by 53 ± II and 85 ± 4%, before and after 
pretreatment with cimetidine (p < 0.01 comparing before 
and after), respectively. Thus, the histamine challenge in 
this study was performed after the pretreatment with ci-
metidine. Coronary arteriography was performed I minute 
after the intravenous administration of histamine and 2 min-
utes after the intravenous administration of nitroglycerin. 
An interval of 5 or more minutes was allowed between 
coronary arteriograms because we had confirmed that the 
vasodilatory effect of contrast medium on the epicardial 
coronary artery continues for this length of time (21). We 
also noted that the vasQdilatory effect of nitroglycerin con-
tinues for at least 15 minutes (22), and successive studies 
with other vasoactive agents were performed at '30 or more 
minute intervals after the nitroglycerin study. 
In the third month after the denudation, coronary artery 
spasm was provoked by intracoronary administration of his-
tamine, 200 j.Lg, after intravenous pretreatment with ci-
metidine, 60 mg/kg (19). After recovery from the histamine-
induced coronary artery spasm, the roles of thromboxane 
A2 and prostacyclin in the occurrence of coronary artery 
spasm were examined. First, thiothromboxane A2, a stable 
thromboxane A2 analog (23), in a dose of 200 j.Lg in 0.2 
ml of 20% ethanol buffer, was administered by intracoro-
nary injection to seven pigs. Coronary cineangiograms were 
obtained I and 5 minutes after this administration. Second, 
indomethacin, a cyclooxygenase inhibitor (24), was admin-
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istered intravenously in doses of 2 mg/kg (25) to four pigs. 
Indomethacin was dissolved with 10 ml of 0.2% sodium 
bicarbonate and the pH was adjusted to 8.0 with diluted 
hydrochloric acid. Thirty minutes later, the provocation of 
coronary artery spasm by intracoronary administration of 
histamine was examined. Third, the sodium salt of pros-
tacyclin dissolved in glycine buffer (pH 10) was adminis-
tered intravenously by a constant-flow pump (Truth, Nak-
agawa Seikodo) at a rate of 50 ng/kg per min (26) to eight 
pigs. During the infusion, temperature of the prostacyclin 
solution was kept constant at 2°C. Under this condition, the 
provocation of the spasm by histamine was tested. 
At the end of these prostanoid studies, diphenhydramine, 
a histamine HI-receptor blocking agent, was administered 
intravenously in a dose of I mg/kg. Then, intracoronary 
administration of histamine after pretreatment with cime-
tidine was repeated to examine the antispastic effect of 
diphenhydramine. 
Measurements. Details have been reported (20); there-
fore, a brief summary will be given: cinefilms were projected 
on a viewing screen (Tagamo 35-CX); matched end-dia-
stolic frames were selected and photocopies (13 x 18 cm) 
were made for measurements of the luminal diameter of the 
coronary arteries. The measurements were performed using 
a caliper to 0.05 mm and the absolute inner diameter (mm) 
of the coronary arteries was obtained from a reference di-
ameter of the Kifa catheter. Reproducibility of the mea-
surements was tested by comparing the data obtained by 
individual observers. There was excellent correlation be-
tween the repeated measurements (r = 0.96, p < 0.001) 
and between the findings of different observers (r = 0.95, 
P < 0.001). 
Definition of coronary artery spasm and ischemic 
electrocardiographic changes. Coronary artery spasm was 
defined as the transient excess vasoconstriction that subsides 
either spontaneously or after the administration of nitro-
glycerin. It is characterized by a reduction of more than 
75% in coronary artery diameter, compared with that at 2 
minutes after intravenous administration of nitroglycerin given 
in doses of 20 j.Lg/kg (19) to avoid the possible influence 
of differences in coronary artery tone (27). Significant isch-
emic electrocardiographic changes were defined as more 
than 0.1 mV ST segment elevation or a depression from the 
control level in more than two leads (19). 
Statistical analysis. Student's t test was used for statis-
tical analysis, and the time sequence data were compared 
using an analysis of variance. A probability value of less 
than 0.05 was considered statistically significant. All results 
are expressed as mean values ± standard error of the mean. 
Results 
Changes in body weight and serum cholesterol. 
Among 18 pigs subjected to coronary endothelial balloon 
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Table 1. Effects of Thiothromboxane A2 on Coronary Diameter and Hemodynamics (n = 7) 
CoD (mm) or 6CoO (%) 
HR sAoP dAoP mAoP 
0 D' C (beats/min) (mm Hg) (mm Hg) (mm Hg) 
Control 2.50 ± 0.14 mm 2.54 ± 0.15 mm 2.54 ± 0.06 mm 100 ± 8 121 ± 9 92 ± 7 108 ± 8 
STA" 200 f.Lg ic 
I minute 27 ± 2% 24 ± 2O/C 23 ± 2% 163 ± 8t 126 ± 7 104 ± 6 113 ± 7 
5 minutes 33 ± 2% 31 ± 2% 29 ± 3% 136 ± 12* 116 ± 6 94 ± 6 105 ± 6 
Cimetidine, 60 mg/kg iv, 81 ± 3%:1= 36 ± 1% 34 ± I ')'f 194 ± 6t :j: 121 ± 5 88 ± 7 100 ± 7 
+ histamine, 200 f.Lg ic 
* p < 0.05; t P < 0.05 vs. control; + p < 0.01 vs. STA, 200 f.Lg intracoronary (ic) (5 minutes). C = nondenuded contralateral coronary artery; 
CoD (mm) = coronary artery diameter; 0 = denuded portion of the left coronary artery; 0' = non denuded portion of the denuded coronary artery; 
6CoO (%) = % decrease in coronary artery diameter from that seen 2 minutes after nitroglycerin, 20 f.Lg/kg; dAoP = diastolic aortic pressure; tJR = 
heart rate; mAoP = mean aortic pressure; sAoP = systolic aortic pressure: ST A, = thiothromboxane A,; I minute, 5 minutes = I and 5 minutes after 
intracoronary administration of STA" 200 f.Lg; iv = intravenous administration. 
denudation, 2 pigs died of ventricular fibrillation during the 
denudation and 2 died suddenly the next day. Hence, the 
two experimental periods, before the denudation and 3 months 
after, incluqed 18 and 14 pigs, respectively. Body weight 
increased significantly from the control level of 15 ± I to 
29 ± I kg after 3 months (p < 0.01). Serum cholesterol 
increased significantly from the control level of 57 ± 5 to 
136 ± 22 mg/dl after 3 months (p < 0.01). 
Provocation of coronary artery spasm. Before endo-
thelial denudation, coronary artery spasm was not provoked. 
In the third month after the denudation and high cholesterol 
feeding, coronary artery spasm was provoked along the 
denuded portion of the coronary artery by intracoronary 
administration of histamine and in the presence of cimeti-
dine, 60 mg/kg administered intravenously, in all (n = 13) 
except I pig in which hypercontraction (66% reduction in 
coronary artery diameter) was induced by histamine, Sig-
nificant ischemic electrocardiographic changes were evident 
in six, ST segment elevation in four and ST segment depres-
sion in two. 
After intracoronary administration of thiothromboxane 
A2 , 200 f.Lg. heart rate increased with no significant change 
in aortic pressure, from 100 to 163 beats/min after I minute 
(p < 0.01), and decreased to 136 beats/min after 5 minutes 
(p < 0,05) (Table I). Thiothromboxane A2 markedly con-
stricted all the epicardial coronary arteries, but failed to 
provoke coronary artery spasm in all seven pigs (Fig, 1). 
Although the degrees of vasoconstriction by thiothrombox-
ane A2, 200 f.Lg (5 minutes), and histamine, 200 f.Lg, in the 
presence of intravenously administered cimetidine, 60 mglkg, 
did not differ in the nondenuded portion of the artery (31 
vs. 36%) or in the nondenuded, contralateral coronary artery 
(29 vs. 34%), the vasoconstriction induced by thio-
thromboxane A2 was not augmented along the denuded por-
tion, compared with the remarkable hypercontraction (vaso-
spasm) induced by histamine (33 vs. 81 %, P < 0.01) (Table 
I) . 
After intravenous administration of indomethacin. 2 I1lg/ kg. 
aortic pressure increased transiently along with a decrease 
in heart rate; however, 30 minutes after the administration, 
mean aortic pressure reverted to the control level (118 vs. 
10 I mm Hg) along with an increase in heart rate (132 vs. 
Figure 1. Thiothromboxane A2 study: angiograms in the control 
state (A), after intracoronary administration of thiothromboxane 
A2 , 200 f.Lg (B) and after intravenous administration of nitroglyc-
erin, 20 f.Lg/kg (e). Thiothromboxane A2 markedly constricted all 
the epicardial coronary arteries but failed to provoke coronary 
artery spasm. 
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Table 2. Effects of Indomethacin on Hemodynamics, Coronary Diameter and Prevention of Histamine-Induced Coronary Spasm 
CoD (mm) or 6CoO (%) 
HR sAoP dAoP mAoP 
0 0' C (beats/min) (mm Hg) (mm Hg) (mm Hg) 
Control study 
Control 2.41 ± 0.06 mm 2.44 ± 0.09 mm 2.48 ± 0.12mm 132 ± 13 135 ± II 102 ± 10 118 ± 12 
Cimetidine iv 87 ± 5%t 36 ± 2% 32 ± 2% 173 ± 16 125 ± 9 67 ± 9 86 ± 9 
+ histamine ic 
Indomethacin study 
Indomethacin iv 15 ± 2%t 15 ± 2%t 16 ± 2%t 179 ± lIt 120 ± II 92 ± 12 101 ± 12 
Cimetidine iv 86 ± 5%:1: 29 ± 5% 31 ± 3% 199 ± 3 118 ± II 65 ± II 83 ± II 
+ histamine ic 
* p < 0.05; t p < 0.01 vs. control study + p < 0.05; :I: p < 0.01 vs. control, nondenuded coronary artery (C). The degrees of vasoconstriction 
by indomethacin, 2 mg/kg intravenously (iv), are expressed as % change in coronary artery diameter (CoD) from that in the control state. The degree 
of vasoconstriction by intracoronary (ic) histamine, 200 J.tg, in the presence of cimetidine, 60 mg/kg iv, is expressed as % change in coronary artery 
diameter (6CoO) from that seen 2 minutes after nitroglycerin, 20 J.tg/kg iv, as the definition of coronary artery spasm; other abbreviations as in Table I. 
179 beats/min) (p < 0.01) (Table 2). Indomethacin non-
selectively constricted the coronary arteries by 15 to 16% 
(Fig. 2). 
Prevention of histamine-induced coronary artery 
spasm. During the intravenous administration of prosta-
Figure 2. Indomethacin study: angiograms in the control state 
(A), aft\!r intravenous administration of indomethacin, 2 mg/kg 
(C), and diphenhydramine, I mg/kg (E), and after intracoro-
nary (ic) administration of histamine, 200 j.tg, with pretreatment 
with cimetidine, 60 mg/kg intravenously (iv) in the control state 
(B) and in the presence of indomethacin (P) and diphenhydra-
mine (F). Indomethacin failed to prevent histamine-induced coro-
nary artery spasm (D), which was completely prevented by diphen-
hydramine (F). 
Control 
Cimetidine 
60mg/kg iv 
+ 
Histamine 
200j.tg ic 
Control 
B 
cyelin, 50 ng/kg per min, aortic pressure decreased from 
107 mm Hg in the control state to 83 mm Hg (p < 0.05) 
and heart rate increased from 103 beats/min in the control 
state to 141 beats/min (p < 0.01) (Table 3). Prostacyelin 
slightly and nonselectively dilated the coronary arteries (4 
to 5% in the three portions of the coronary arteries) and 
failed to prevent the histamine-induced coronary artery spasm 
in all eight pigs (Fig. 3). 
After intravenous pretreatment with indomethacin. 2 
mg/kg. histamine induced coronary artery spasm in a manner 
similar to that seen before pretreatment in all four pigs 
examined. Diphenhydramine, a histamine HI-receptor 
blocking agent, prevented histamine-induced coronary ar-
tery spasm in all four pigs (Fig. 2). 
Indomethacin 
(2mg/kg iv) 
Diphenhydramine 
(1mg/kg iv) 
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Table 3. Effects of Prostacyclin on Hemodynamics, Coronary Diameter and Prevention of Histamine-Induced Coronary Spasm 
CoD (mm) or 6 CoD (%) 
HR sAoP dAoP mAoP 
0 0' C (beats/min) (mmHg) (mm Hg) (mm Hg) 
Control study 
Control 2.53 ± 0.12 mm 2.50 ± 0.14 mm 2.56 ± 0.05 mm 103 ± 7 119 ± 7 91 ± 6 107 ± 7 
Cimetidine iv 82 ± 3%t 36 ± 1% 33 ± 1% 194 ± 6 121 ± 5 88 ± 7 100 ± 7 
+ histamine ic 
PGIz study 
PGIz div -5 ± 1%* -5 ± 1%* -4 ± 1%* 141 ± 11* 97 ± 5* 72 ± 6* 83 ± 6* 
Cimetidine iv 79 ± 3%t 35 ± 2% 35 ± 1% 186 ± 6 110 ± 3 71 ± 5 83 ± 5 
+ histamine ic 
* p < 0.05; t p < 0.01 vs. control study t p < 0.01 vs. control, nondenuded coronary artery (C). The degree of vasodilation (minus) by prostacyclin 
(PGIz), 50 ng/kg per min, is expressed as % change in coronary artery diameter (CoD) from that in the control state. The degree of vasoconstriction 
(plus) by intracoronary (ic) histamine, 200 /-tg, in the presence of cimetidine, 60 mg/kg, intravenously (iv) is expressed as % change in coronary artery 
diameter from that seen 2 minutes after nitroglycerin, 20 /-tg/kg iv, as the definition of coronary artery spasm; other abbreviations as in Table I. 
Discussion 
The salient features of the present study are that thio-
thromboxane A2 or indomethacin did not induce coronary 
artery spasm, and prostacyclin or pretreatment with indo-
methacin did not prevent histamine-induced coronary spasm. 
These results suggest that acute changes in the levels of 
prostanoids had no effect on coronary artery spasm in our 
in vivo swine modeL 
Animal models of coronary artery spasm. Kawachi et 
aL (20) denuded the endothelium of a canine coronary artery 
and noted a significant vasoconstriction due to ergonovine 
along the denuded portion. However, the vasoconstriction 
was less than 40%, a level that will not cause myocardial 
ischemia, We chose the G6ttingen miniature pig as a model 
in which enhanced vasoconstriction was repeatedly docu-
mented after de-endothelialization by intracoronary admin-
istration of histamine, 200 p,g, after pretreatment with ci-
metidine, an Hz-receptor blocking agent (19), A rather large 
dose of histamine was used to constrict the denuded portion 
by more than 70%; however, the hemodynamic effect of 
histamine was not so serious and vasoconstriction was to-
tally prevented by a clinical dose of the HI-receptor blocker 
diphenhydramine, Accordingly, this provocation of coro-
nary spasm by histamine, 200 p,g, is considered to be a 
useful tool to analyze the pathophysiology and pharmaco-
Control PG b 
(SOng/kg/min div) 
Nitroglycerin 
(20J.Lg/kg iv) 
Control 
Cimetidine 
60mg/kg iv 
+ 
Histamine 
200J.Lg ic 
Figure 3. Prostacyclin (PG lz) study: an-
giograms obtained in the same pig shown 
in Figure 2 in the control state (A), after 
intravenous (iv) administration of prosta-
cyclin, (C) and nitroglycerin (E) and after 
intracoronary (ic) administration of hista-
mine with intravenous pretreatment with ci-
metidine in the control state (B) and after 
prostacyclin (D). Prostacyclin infusion failed 
to prevent histamine-induced coronary ar-
tery spasm (D). 
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dynamics of regional coronary spasm produced in miniature 
pigs. 
Thromboxane A2 as a vasospastic agent. Thio-
thromboxane Az is a stable analog of thromboxane Az that 
has a potent vasoconstrictor effect and platelet-aggregating 
activity (23). Our results suggest that exogenously admin-
istered thromboxane A2 did not provoke coronary artery 
spasm in our swine model. In the clinical field, elevated 
levels of thromboxane B2, a stable end-metabolite of throm-
boxane A2, have been reported (12,14,15); however, Rob-
ertson et al. (18) stated that this elevated thromboxane B2 
level is a result rather than a cause of coronary artery spasm 
because thromboxane B2 did not increase just before va-
sospastic attacks and increased later after the attacks. In the 
present study, intracoronary administration of thiothrom-
boxane A2, 200 J-Lg, or histamine, 200 J-Lg, in the presence 
of cimetidine, induced the same extent of vasoconstriction 
in the nondenuded portion of the denuded artery or non-
denuded contralateral coronary artery; however, in the de-
nuded, atheromatous portion, histamine-induced coronary 
artery spasm and thiothromboxane A2 did not induce an 
augmented vasoconstrictive response. In preliminary stud-
ies, we noted an enhanced vasoconstriction by histamine 
after pretreatment with the Hz-receptor blocker cimetidine. 
Therefore, the histamine HI-receptor and not the throm-
boxane Az-receptor may be activated along the denuded, 
atheromatous portion of the coronary artery, and spasm 
occurs. 
In our swine model, indomethacin constricted the coro-
nary arteries in the same manner seen clinically (28), prob-
ably because of blockade of the vasodilative-prostaglandin 
synthesis. The data we obtained coincide with clinical data 
on the failure of a cyclooxygenase inhibitor such as aspirin 
(29) or indomethacin (30) to prevent coronary artery spasm. 
Prostacyclin as a preventive agent for histamine-in-
duced coronary spasm. We found that prostacyclin in-
fusion caused hemodynamic effects similar to those seen in 
humans (31) or dogs (32), thereby suggesting the systemic 
vasodilatory effects of the drug. In open chest dogs, we 
found that prostacyclin significantly dilated the large coro-
nary artery (26). Clinically, the beneficial effects of pros-
tacyclin for the prevention of ischemic episodes are contro-
versial. Szczelik et al. (33) reported the beneficial effect of 
intravenous drip infusion of prostacyclin for 72 hours to 
prevent ischemic episodes in all seven patients with angina 
at rest who did not respond to therapy with oral nitrates. In 
contrast, Chierchia et al. (34) reported an incomplete effect 
of prostacyclin in preventing spontaneous ischemic epi-
sodes, as characterized by electrocardiographic changes in 
eight of nine patients with variant angina. Although the 
action of exogenous prostacyclin on the swine coronary 
circulation is not fully understood, at least in our swine 
model, prostacyclin had no preventive effect on coronary 
artery spasm induced by histamine. 
lACC Vol. 6, No.2 
August 1985:321-7 
Conclusions. In our swine model of coronary artery 
spasm, the prostanoids may not playa primary role in the 
occurrence of the spasm. However, the results of this study 
cannot necessarily be extrapolated to cases of clinical spasm, 
because there are differences in vascular response to pros-
taglandins relating to species, tissues, locations and aging. 
Basic and clinical studies should shed more light on the role 
of the prostaglandins in the pathogenesis of coronary artery 
spasm. 
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